Gilder Gagnon Howe & CO LLC Sigilon Therapeutics, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$4.42 - $10.61 $374,369 - $898,656	-84,699 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$9.15 - $20.17 $5.21 Million - $11.5 Million	-569,510 Reduced 87.05%	84,699 $909,000
Q1 2021 May 17, 2021	SELL	$18.76 - $40.91 $150,417 - $328,016	-8,018 Reduced 1.21%	654,209 $14.6 Million
Q4 2020 Feb 16, 2021	BUY	$27.6 - $48.03 $18.3 Million - $31.8 Million	662,227 New	662,227 $31.8 Million

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.